Adams Wealth Management Buys New Position in Gilead Sciences, Inc. $GILD

Adams Wealth Management purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,893 shares of the biopharmaceutical company’s stock, valued at approximately $653,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Caldwell Trust Co purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $121,000. Valeo Financial Advisors LLC raised its holdings in Gilead Sciences by 26.9% in the second quarter. Valeo Financial Advisors LLC now owns 13,278 shares of the biopharmaceutical company’s stock valued at $1,472,000 after acquiring an additional 2,811 shares in the last quarter. NWF Advisory Services Inc. lifted its stake in Gilead Sciences by 16.0% in the second quarter. NWF Advisory Services Inc. now owns 2,162 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 299 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Gilead Sciences by 3.6% in the second quarter. Osaic Holdings Inc. now owns 204,115 shares of the biopharmaceutical company’s stock worth $22,650,000 after acquiring an additional 7,166 shares during the last quarter. Finally, Total Investment Management Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $61,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.3%

NASDAQ:GILD opened at $120.40 on Monday. The company has a market capitalization of $149.38 billion, a PE ratio of 18.67, a P/E/G ratio of 0.67 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The stock’s 50 day moving average price is $121.89 and its 200 day moving average price is $115.81. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Scotiabank assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. The Goldman Sachs Group upped their price objective on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. HSBC raised their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $131.13.

Insider Buying and Selling at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This trade represents a 1.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 130,257 shares of company stock valued at $15,991,492. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.